Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CP101 for Ulcerative Colitis
NCT05852574Phase 1Active, not recruiting
- Sponsor
- Brigham and Women's Hospital
- Start
- Sep 2023
- Primary completion
- Nov 2024
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of CP101 in ulcerative colitis (UC) (2 arms), sponsored by Brigham and Women's Hospital. Primary endpoints: Engraftment of CP101-associated microbes at 8 weeks and Safety and tolerability of CP101 at 8 weeks. Started Sep 2023; status: active, not recruiting.
02
Drugs
CP101
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05852574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05852574.